Skip to content
Therapy But Better – Lifestyle
Author:
RenovoRx, Inc.
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
May 19, 2026
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
May 14, 2026
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
April 29, 2026
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
April 23, 2026
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
April 14, 2026
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
April 8, 2026
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
April 1, 2026
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
March 30, 2026
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
March 26, 2026
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
March 23, 2026
1
2
Next Page
→